2026 ASCO LBA | Juncell Therapeutics' GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma
SHANGHAI, June 3, 2026 /PRNewswire/ -- On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Lu Si from Peking University Cancer Hospital presented the results of a Pivotal Phase 2...
SHANGHAI, June 3, 2026 /PRNewswire/ -- On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Lu Si from Peking University Cancer Hospital presented the results of a Pivotal Phase 2...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.